UNSPSC 51131755: Vorapaxar sulfate

A type of protease-activated receptor-1 (PAR-1) antagonist.

UNSPSC 51131755 Vorapaxar sulfate, a Commodity code, captures pharmaceutical procurement by state and local governments, though the code's nominal scope does not align cleanly with recent solicitation activity. The three most recent state and local opportunities posted under or near this code show minimal direct demand for vorapaxar sulfate specifically. Instead, they reflect broader pharmaceutical sourcing patterns: the City of Tampa's IFB for Advanced Life Support Medications (posted April 24, 2026, due April 8, 2026) solicited four specific emergency-response drugs—labetalol, epinephrine, adenosine, and diltiazem—for Tampa Fire Rescue with a 120-day award window and an estimated contract value of $40,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) targeted manufacturers of established generic drugs distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with pricing weighted at 75 percent and contract terms through June 30, 2028. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026, response deadline April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies include municipal fire departments, state health agencies, and multi-state cooperative purchasing vehicles.

Geographic activity centers on Texas, Minnesota (with participating state and local partners including Oregon), and Florida, though the limited recent opportunities suggest moderate activity under this specific code. The Tampa solicitation reflects municipal emergency-services demand and included a 5 percent SLBE bid discount (not to exceed $10,000) with accessibility and OSHA Safety Data Sheet compliance requirements. The MMCAP RFP required Current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and multi-wholesaler relationships, with performance penalties of $200 to $1,500 per violation. The Texas RFI represents exploratory procurement activity with no award value or formal evaluation criteria specified at the information-gathering phase. Recent opportunities show state and local governments buying established, commodity-priced generic pharmaceuticals for emergency response, public health programs, and employee health plans, with cooperative purchasing and direct-manufacturer relationships increasingly relevant to procurement strategy.